Navigation Links
GeoVax Reports Progress on Its AIDS Vaccine Technology
Date:7/7/2008

, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccination, anti-viral drug treatment was stopped and the animals were monitored to determine whether the vaccine could control the SIV infection during the absence of the drugs.

The outstanding results from the study revealed the vaccine controlling the infection in the absence of drugs. In one primate, the reduction in viral levels over pre-drug treatment and vaccination levels was 1000 times. In the other, the reductions in viral levels were 100 times. The excellent control of the virus infection in the absence of drug treatment was associated with the vaccine raising the types of CD4 and CD8 T cells that are found in the rare individuals who spontaneously control their HIV infections.

Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been initiated. The intent of therapeutic vaccination is for the vaccine to "control" HIV virus levels in infected individuals to very low levels thus blocking the development of AIDS. Successful therapeutic AIDS vaccination programs with GeoVax vaccines would lead to reduction in the use of costly anti-HIV medications and their often harmful side effects.

Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and Development, commented, "I had not anticipated the extent of vaccine control that was achieved in the already infected non-human primates. These are highly promising results that need to be extended into infected humans to see if the vaccine can be used to reduce the need for taking drugs. The results also warrant more extended studies in already infected non-human primates to explore parameters that both limit and enhance the ability for a vaccine to disp
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GeoVax Secures $10 Million Financing Commitment
2. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
3. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
4. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
5. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
6. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
7. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
8. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
11. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 /PRNewswire-iReach/ -- Nitrosolution.com, a website ... , will celebrate its first anniversary in August. The ... designed to enhance the body,s ability to produce nitric ... is made up of a variety of phytonutrients and ... been found to increase nitric oxide production ...
(Date:7/21/2014)... YORK , July 21, 2014  EHE International, ... exams with a nationwide physician network, today announced that ... Las Vegas, NV has been named an ... the Las Vegas region now ... help proactively maintain their health. "EHE ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
Breaking Medicine Technology:Up and Coming Nitric Oxide Supplements Company Nitrosolution.com Celebrates its One Year Anniversary 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5
... Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... Pfizer Inc,s (NYSE: PFE ) phase III ... CCR5-tropic,HIV-1, increased efficacy was shown as a result ... of the enhanced version of Monogram,s Trofile(TM),Assay., ...
... Oct. 26 Paratek Pharmaceuticals, Inc. today,announced positive ... PTK,0796, a first-in-class aminomethylcycline (AMC). The Phase 2 ... (IV) forms of PTK 0796 to,Zyvox(R) in the ... infections (cSSSIs). Paratek,s trial met its primary safety ...
Cached Medicine Technology:Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 2Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 3Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 4Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 5Data Reported at ICAAC Indicates Selzentry(TM) Phase III Treatment-Naive Trial Shows Increased Efficacy When Used With Enhanced Trofile(TM) Assay 6Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 As part ... School of Medicine at Mount Sinai have helped identify ... the risk of developing schizophrenia, in the largest genomic ... with 80,000 people. The findings, published online in Nature, ... schizophrenia, and could lead to new approaches to treating ...
(Date:7/22/2014)... Alan Mozes HealthDay Reporter ... used to treat moderate-to-severe allergic asthma appears to offer relief ... standard medications, new research suggests. The prescription drug -- ... U.S. Food and Drug Administration approval earlier this year for ... is taken at a high dose for a six-month period ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... 2014 The “Human Insulin Market ... Acting, Premixed), Modern Human Insulin (Rapid Acting, Long ... Novomix, Tresiba, Others) - Forecast to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 For more ... and cold storage consumers with dynamic, specialized ... and customer satisfaction. Offering 50-70% less energy requirements ... process. This process is completed through a non-chemical ... technologies also provide a 4.2 Micron droplet. The ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 2Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 3Health News:Mount Sinai Scientists and International Team Shed New Light on Schizophrenia in Largest Genomic Study Published to Date 4Health News:Asthma Drug May Help Those With Chronic Hives 2Health News:Asthma Drug May Help Those With Chronic Hives 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets 5Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 2Health News:Smart Fog Inc Announces Cold Storage Humidification Technology to be Exhibited at the 2014 Fresh Summit Convention & Expo 3
... pioneer and global market leader in acai, with certified ... nationwide from Whole Foods to Publix, Kroger and Safeway, ... false claims by acai scam campaigns and consumer watchdog ... locals for centuries, is a highly nutritious fruit scientifically ...
... in football as it hosts conference chaired by its medical director ... ... Gulf Breeze, FL (Vocus) March 27, 2009 -- The fourth annual ... Orthopaedics & Sports Medicine will attract top physicians, physical therapists ...
... Sky One,Medical, Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter,drugs in the People,s Republic of ... call at 10:30 a.m. Eastern Daylight Time (EDT) on ... fiscal year 2008 financial,results. , ...
... concentrating in areas with high doctor/patient ratios, experts say ... and urban areas of the United States may soon ... for underserved and aging populations, a new study warns. ... areas with already established medical communities, a trend that ...
... School of Medicine have been named Early Career Scientists ... Iannis Aifantis, Ph.D. associate professor of pathology, co-director of ... Institute and Jeremy S. Dasen Ph.D., assistant professor of ... among 50 of the nation,s top scientists being honored ...
... passed today by the Democratically-controlled Michigan House of ... pockets of personal injury lawyers at the expense ... Commerce."By repealing Michigan,s lawsuit abuse protections, the supporters ... becomes a lawsuit magnet," said Wendy Block, Director ...
Cached Medicine News:Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 2Health News:Sambazon, World Leader in Acai, Stands up for the Amazonian Fruit's True Nutritional Properties 3Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 2Health News:Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference 3Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth and Fiscal Year 2008 Results 2Health News:Midwest and Northeast May Face Surgeon Shortage 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 2Health News:Two NYU Scientists Named Howard Hughes Medical Institute's early career scientists 3